Componentes:
Medicamente revisado por Fedorchenko Olga Valeryevna, Farmácia Última atualização em 21.05.2022
Atenção! As informações na página são apenas para profissionais de saúde! As informações são coletadas em fontes abertas e podem conter erros significativos! Tenha cuidado e verifique novamente todas as informações desta página!
20 principais medicamentos com os mesmos componentes:
Adults: Recommended Dose: 50 mg daily (150-mg tab taken orally 3 times a day before meals). The dose may be reduced according to the patient's age and symptoms.
Duration of Treatment: In clinical studies, Itopride (Tazol-IT) has been administered up to 8 weeks.
Recommended Dosing Schedule
Pantoprazole (Tazol-IT) is supplied as delayed-release granules in packets for preparation of oral suspensions or as delayed-release tablets. The recommended dosages are outlined in Table 1.
Table 1: Recommended Dosing Schedule for Pantoprazole (Tazol-IT)
Indication | Dose | Frequency |
Short-Term Treatment of Erosive Esophagitis Associated With GERD | ||
Adults | 40 mg | Once daily for up to 8 weeks* |
Children (5 years and older) | ||
≥ 15 kg to < 40 kg | 20 mg | Once daily for up to 8 weeks |
≥ 40 kg | 40 mg | |
Maintenance of Healing of Erosive Esophagitis | ||
Adults | 40 mg | Once daily*** |
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome | ||
Adults | 40 mg | Twice daily** |
* For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of Pantoprazole (Tazol-IT) may be considered. ** Dosage regimens should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 240 mg daily have been administered. *** Controlled studies did not extend beyond 12 months |
Administration Instructions
Directions for method of administration for each dosage form are presented in Table 2.
Table 2: Administration Instructions
Formulation | Route | Instructions* |
Delayed-Release Tablets | Oral | Swallowed whole, with or without food |
For Delayed-ReleaseOral Suspension | Oral | Administered in 1 teaspoonful of applesauce or apple juice approximately 30 minutes prior to a meal |
For Delayed-ReleaseOral Suspension | Nasogastric tube | See instructions below |
* Patients should be cautioned that Pantoprazole (Tazol-IT) Delayed-Release Tablets and Pantoprazole (Tazol-IT) For Delayed-ReleaseOral Suspension should not be split, chewed, or crushed. |
Pantoprazole (Tazol-IT) Delayed-Release Tablets
Pantoprazole (Tazol-IT) Delayed-Release Tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of Pantoprazole (Tazol-IT) Delayed-Release Tablets.
Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension
Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension should only be administered approximately 30 minutes prior to a meal via oral administration in apple juice or applesauce or nasogastric tube in apple juice only. Because proper pH is necessary for stability, do not administer Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension in liquids other than apple juice, or foods other than applesauce.
Do not divide the 40 mg Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension packet to create a 20 mg dosage for pediatric patients who are unable to take the tablet formulation.
Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension -Oral Administration in Applesauce
- Open packet.
- Sprinkle granules on one teaspoonful of applesauce. DO NOT USE OTHER FOODS OR CRUSH OR CHEW THE GRANULES.
- Take within 10 minutes of preparation.
- Take sips of water to make sure granules are washed down into the stomach. Repeat water sips as necessary.
Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension -Oral Administration in Apple Juice
- Open packet.
- Empty granules into a small cup or teaspoon containing one teaspoon of apple juice.
- Stir for 5 seconds (granules will not dissolve) and swallow immediately.
- To make sure that the entire dose is taken, rinse the container once or twice with apple juice to remove any remaining granules. Swallow immediately.
Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension -Nasogastric (NG) Tube or Gastrostomy Tube Administration
For patients who have a nasogastric tube or gastrostomy tube in place, Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension can be given as follows:
- Remove the plunger from the barrel of a 2 ounce (60 mL) catheter-tip syringe. Discard the plunger.
- Connect the catheter tip of the syringe to a 16 French (or larger) tube.
- Hold the syringe attached to the tubing as high as possible while giving Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension to prevent any bending of the tubing.
- Empty the contents of the packet into the barrel of the syringe.
- Add 10 mL (2 teaspoonfuls) of apple juice and gently tap and/or shake the barrel of the syringe to help rinse the syringe and tube. Repeat at least twice more using the same amount of apple juice (10 mL or 2 teaspoonfuls) each time. No granules should remain in the syringe.
How supplied
Dosage Forms And Strengths
Delayed-Release Tablets
- 40 mg, yellow oval biconvex tablets imprinted with Pantoprazole (Tazol-IT) (brown ink) on one side
- 20 mg, yellow oval biconvex tablets imprinted with P20 (brown ink) on one side
For Delayed-Release
Oral Suspension
- 40 mg, pale yellowish to dark brownish, enteric-coated granules in a unit dose packet
Storage And Handling
Pantoprazole (Tazol-IT) (Pantoprazole (Tazol-IT) sodium) Delayed-Release Tablets are supplied as 40 mg yellow, oval biconvex delayed-release tablets imprinted with Pantoprazole (Tazol-IT) (brown ink) on one side and are available as follows:
NDC 0008-0841-81, bottles of 90
NDC 0008-0841-99, carton of 10 Redipak® blister strips of 10 tablets each
Pantoprazole (Tazol-IT) (Pantoprazole (Tazol-IT) sodium) Delayed-Release Tablets are supplied as 20 mg yellow oval biconvex delayed-release tablets imprinted with P20 (brown ink) on one side and are available as follows:
NDC 0008-0843-81, bottles of 90
Pantoprazole (Tazol-IT) (Pantoprazole (Tazol-IT) sodium) For Delayed-Release
Oral Suspension
NDC 0008-0844-02, unit-dose carton of 30
Storage
Store Pantoprazole (Tazol-IT) For Delayed-Release
Oral Suspension and Pantoprazole (Tazol-IT) Delayed-Release Tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).
Distributed by : Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc., Philadelphia, PA 19101. under license from Takeda GmbH D78467 Konstanz, Germany. Revised: December 2014
Hipersensibilidade ao cloridrato de Itoprida (Tazol-IT) ou a qualquer um dos excipientes do Itopride (Tazol-IT).
Pacientes em quem um aumento na motilidade gastrointestinal pode ser prejudicial, por exemplo, hemorragia gastrointestinal, obstrução mecânica ou perfuração.
Veja também:
Qual é a informação mais importante que devo saber sobre o pantoprazol (Tazol-IT)?
A azia é frequentemente confundida com os primeiros sintomas de um ataque cardíaco. Procure atendimento médico de emergência se tiver dor no peito ou sensação de peso, dor se espalhando pelo braço ou ombro, náusea, sudorese e um mal-estar geral.
Você não deve usar este medicamento se for alérgico ao pantoprazol (Tazol-IT) ou a qualquer outro medicamento com benzimidazol, como albendazol (Albenza) ou mebendazol (Vermox).
O pantoprazol (Tazol-IT) não é para alívio imediato dos sintomas de azia.
Tome este medicamento pelo período de tempo prescrito. Seus sintomas podem melhorar antes que a condição seja totalmente tratada.
O pantoprazol (Tazol-IT) não deve ser tomado juntamente com o atazanavir (Reyataz) ou nelfinavir (Viracept). Informe o seu médico se estiver a tomar um destes medicamentos para tratar o VIH ou a SIDA
Algumas condições devem ser tratadas a longo prazo com Pantoprazol (Tazol-IT). O uso crônico de pantoprazol (Tazol-IT) causou câncer de estômago em estudos com animais, mas não se sabe se este medicamento teria os mesmos efeitos em humanos. Converse com seu médico sobre seu risco específico de desenvolver câncer de estômago.
O tratamento a longo prazo com Pantoprazol (Tazol-IT) também pode dificultar a absorção da vitamina B-12 pelo corpo, resultando em uma deficiência dessa vitamina. Converse com seu médico se precisar de tratamento prolongado com pantoprazol (Tazol-IT) e se preocupar com a deficiência de vitamina B-12.
Use Pantoprazole (Tazol-IT) suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Pantoprazole (Tazol-IT) suspension comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Pantoprazole (Tazol-IT) suspension refilled.
- Take Pantoprazole (Tazol-IT) suspension by mouth on an empty stomach about 30 minutes before a meal.
- Do not crush or chew Pantoprazole (Tazol-IT) suspension.
- Do not divide the contents of the packet to make a smaller dose.
- Only mix Pantoprazole (Tazol-IT) suspension with applesauce or apple juice. Do not mix with water or other liquids or foods.
- If you are mixing Pantoprazole (Tazol-IT) suspension with applesauce, sprinkle the contents of the packet onto 1 teaspoonful of applesauce. Swallow within 10 minutes after mixing. Take sips of water to make sure the granules are washed down into the stomach.
- If you are mixing Pantoprazole (Tazol-IT) suspension with apple juice, empty the contents of the packet into a small cup containing 5 mL (1 teaspoonful) apple juice. Stir for 5 seconds and then swallow immediately. To be sure you receive all the medicine, rinse the container once or twice with apple juice and swallow immediately.
- If the patient is taking Pantoprazole (Tazol-IT) suspension through a nasogastric (NG) tube or gastric tube, follow the instructions for use in the extra patient leaflet.
- You may take antacids while you are using Pantoprazole (Tazol-IT) suspension if you are directed to do so by your doctor.
- Continue to take Pantoprazole (Tazol-IT) suspension even if you feel well. Do not miss any doses.
- If you miss a dose of Pantoprazole (Tazol-IT) suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Pantoprazole (Tazol-IT) suspension.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Itopride (Tazol-IT) is used to treat heartburn, feeling of stomach fullness and bloating, upper abdominal pain, nausea, vomiting and loss of appetite (anorexia).
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Pantoprazole (Tazol-IT) is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole (Tazol-IT) belongs to a class of drugs known as proton pump inhibitors (PPIs).
OTHER USES: This section contains uses of this drug that are not listed in the approved US professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to treat and prevent stomach and intestinal ulcers.
How to use Pantoprazole (Tazol-IT)
Read the Medication Guide provided by your pharmacist before you start taking Pantoprazole (Tazol-IT) and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor, usually once daily. Dosage and length of treatment are based on your medical condition and response to treatment.
If you are taking the tablets, you may take them with or without food. Swallow the tablets whole. Do not split, crush, or chew the medication. Doing so may destroy the drug.
If you are taking the granules, take your dose 30 minutes before a meal. To take it by mouth, open the packet and mix the granules in applesauce or apple juice. Do not mix with other foods or liquids. Do not crush or chew the granules. Sprinkle the granules on 1 teaspoon (5 milliliters) of applesauce and swallow all of the mixture right away (within 10 minutes). Follow with sips of water. Or you can mix the granules with 1 teaspoon (5 milliliters) of apple juice in a small cup, stir for 5 seconds, and swallow all of the mixture right away. To make sure you take the entire dose, rinse the cup once or twice with apple juice to mix any remaining granules, and swallow the juice. Do not prepare the mixture ahead of time for later use.
If you are giving the granules through a tube into the stomach (nasogastric or gastric tube), ask your health care professional for detailed instructions on how to properly mix and give it.
If needed, antacids may be taken along with this medication. If you are also taking sucralfate, take Pantoprazole (Tazol-IT) at least 30 minutes before sucralfate.
Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. Continue to take this medication for the prescribed length of treatment even if you are feeling better.
Tell your doctor if your condition persists or worsens. The risk of side effects goes up over time. Ask your doctor how long you should take this medication.
Metabolic interactions are not expected since Itopride (Tazol-IT) is primarily metabolized by flavine monooxygenase and not by CYP450.
No changes in protein-binding have been seen with co-administration of warfarin, diazepam, diclofenac sodium, ticlopidine hydrochloride, nifedipine and nicardipine hydrochloride.
Since Itopride (Tazol-IT) has gastrokinetic effects it could influence the absorption of concomitantly orally administered drugs. Particular caution should be taken with drugs with a narrow therapeutic index, sustained-release or enteric-coated formulations.
Antiulcer drugs eg, cimetidine, ranitidine, teprenone and cetraxate do not affect the prokinetic action of Itopride (Tazol-IT).
Anticholinergic drugs may reduce the action of Itopride (Tazol-IT).
See also:
What other drugs will affect Pantoprazole (Tazol-IT)?
Pantoprazole (Tazol-IT) is metabolized through the cytochrome P450 system, primarily the CYP2C19 and CYP3A4 isozymes, and subsequently undergoes Phase II conjugation.
Based on studies evaluating possible interactions of Pantoprazole (Tazol-IT) with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. Clinically relevant interactions of Pantoprazole (Tazol-IT) with other drugs with the same metabolic pathways are not expected. Therefore, when coadministered with Pantoprazole (Tazol-IT), adjustment of the dosage of Pantoprazole (Tazol-IT) or of such drugs may not be necessary. There was also no interaction with concomitantly administered antacids. There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including Pantoprazole (Tazol-IT), and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
Because of profound and long lasting inhibition of gastric acid secretion, Pantoprazole (Tazol-IT) may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
Laboratory Tests
There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including Pantoprazole (Tazol-IT). An alternative confirmatory method should be considered to verify positive results.
Clinical Trials: In clinical trials (phase I-III), Itopride (Tazol-IT) hydrochloride was well-tolerated and no serious adverse reactions were reported. A total of 19 adverse drug reactions in 14 patients were reported out of 572 cases with an incidence of 2.4%. The majority of these adverse reactions occurring in >1 patient consisted of diarrhea in 4 cases (0.7%), headache in 2 cases (0.3%) and abdominal pain in 2 cases (0.3%).
Abnormal laboratory findings observed in the trials include decreased white blood cells (leukocytopenia) in 4 cases (0.7%), increased prolactin in 2 cases (0.3%).
Post Marketing Experience: The following adverse events have been reported in patients receiving Itopride (Tazol-IT) hydrchloride.
Blood and Lymphatic System Disorders: Leukopenia and thrombocytopenia.
Immune System Disorders: Anaphylactoid reaction.
Endocrine Disorders: Increased prolactin level and gynecomastia.
Nervous System Disorders: Dizziness, headache and tremor.
Gastrointestinal Disorders: Diarrhea, constipation, abdominal pain, increased saliva and nausea.
Hepatobiliary Disorders: Jaundice.
Skin and Subcutaneous Tissue Disorders: Rash, redness and itching.
Investigations: Increased aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase (SGOT)], alanine aminotransferase (ALT) [serum glutamic pyruvic transaminase (SGPT)], γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase and bilirubin.
See also:
What are the possible side effects of Pantoprazole (Tazol-IT)?
The adverse reaction profiles for Pantoprazole (Tazol-IT) (Pantoprazole (Tazol-IT) sodium) For Delayed-Release
Oral Suspension and Pantoprazole (Tazol-IT) (Pantoprazole (Tazol-IT) sodium) Delayed-Release Tablets are similar.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adults
Safety in nine randomized comparative US clinical trials in patients with GERD included 1,473 patients on oral Pantoprazole (Tazol-IT) (20 mg or 40 mg), 299 patients on an H2-receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed in Table 3.
Table 3: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of > 2%
Pantoprazole (Tazol-IT) (n=1473) % | Comparators (n=345) % | Placebo (n=82) % | |
Headache | 12.2 | 12.8 | 8.5 |
Diarrhea | 8.8 | 9.6 | 4.9 |
Nausea | 7.0 | 5.2 | 9.8 |
Abdominal pain | 6.2 | 4.1 | 6.1 |
Vomiting | 4.3 | 3.5 | 2.4 |
Flatulence | 3.9 | 2.9 | 3.7 |
Dizziness | 3.0 | 2.9 | 1.2 |
Arthralgia | 2.8 | 1.4 | 1.2 |
Additional adverse reactions that were reported for Pantoprazole (Tazol-IT) in clinical trials with a frequency of ≤ 2% are listed below by body system:
Body as a Whole: allergic reaction, pyrexia, photosensitivity reaction, facial edema
Gastrointestinal: constipation, dry mouth, hepatitis
Hematologic: leukopenia, thrombocytopenia
Metabolic/Nutritional: elevated CK (creatine kinase), generalized edema, elevated triglycerides, liver enzymes elevated
Musculoskeletal: myalgia
Nervous: depression, vertigo
Skin and Appendages: urticaria, rash, pruritus
Special Senses: blurred vision
Pediatric Patients
Safety of Pantoprazole (Tazol-IT) in the treatment of Erosive Esophagitis (EE) associated with GERD was evaluated in pediatric patients ages 1 year through 16 years in three clinical trials. Safety trials involved pediatric patients with EE; however, as EE is uncommon in the pediatric population, 249 pediatric patients with endoscopically-proven or symptomatic GERD were also evaluated. All adult adverse reactions to Pantoprazole (Tazol-IT) are considered relevant to pediatric patients. In patients ages 1 year through 16 years, the most commonly reported ( > 4%) adverse reactions include: URI, headache, fever, diarrhea, vomiting, rash, and abdominal pain.
For safety information in patients less than 1 year of age see Use in Specific Populations.
Additional adverse reactions that were reported for Pantoprazole (Tazol-IT) in pediatric patients in clinical trials with a frequency of ≤ 4% are listed below by body system:
Body as a Whole: allergic reaction, facial edema
Gastrointestinal: constipation, flatulence, nausea
Metabolic/Nutritional: elevated triglycerides, elevated liver enzymes, elevated CK (creatine kinase)
Musculoskeletal: arthralgia, myalgia
Nervous: dizziness, vertigo
Skin and Appendages: urticaria
The following adverse reactions seen in adults in clinical trials were not reported in pediatric patients in clinical trials, but are considered relevant to pediatric patients: photosensitivity reaction, dry mouth, hepatitis, thrombocytopenia, generalized edema, depression, pruritus, leukopenia, and blurred vision.
Zollinger-Ellison Syndrome
In clinical studies of Zollinger-Ellison Syndrome, adverse reactions reported in 35 patients taking Pantoprazole (Tazol-IT) 80 mg/day to 240 mg/day for up to 2 years were similar to those reported in adult patients with GERD.
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of Pantoprazole (Tazol-IT). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
These adverse reactions are listed below by body system:
General Disorders and Administration Conditions: asthenia, fatigue, malaise
Hematologic: pancytopenia, agranulocytosis
Hepatobiliary Disorders: hepatocellular damage leading to jaundice and hepatic failure
Immune System Disorders: anaphylaxis (including anaphylactic shock)
Infections and Infestations: Clostridium difficile associated diarrhea
Investigations: weight changes
Metabolism and Nutritional Disorders: hyponatremia, hypomagnesemia
Musculoskeletal Disorders: rhabdomyolysis, bone fracture
Nervous: ageusia, dysgeusia
Psychiatric Disorders: hallucination, confusion, insomnia, somnolence
Renal and Urinary Disorders: interstitial nephritis
Skin and Subcutaneous Tissue Disorders: severe dermatologic reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN, some fatal), and angioedema (Quincke's edema)
Cada comprimido revestido por película também contém os seguintes ingredientes inativos: Lactose, amido de milho, carmelose, ácido silícico leve anidro, estearato de magnésio, hidroxipropilmetilcelulose 2910 (6 mm2/ s), macrogol 6000, óxido de titânio e cera de carnaúba.
O comprimido revestido por película é formulado para fornecer liberação imediata.
O cloridrato de itopride (Tazol-IT) é o cloridrato de N- (4- (2 (dimetilamino) etoxi) benzil) -3,4-dimetoxibenzamida. O cloridrato de itoprida (Tazol-IT) é uma benzamida substituída. Tem uma fórmula empírica de C20H26N2O4· HCl e um peso molecular de 394,89 g / mol.
O cloridrato de itopride (Tazol-IT) é um cristal branco amarelado branco pálido ou pó cristalino. É inodoro e tem um sabor amargo. É muito solúvel em água, livremente solúvel em metanol ou em ácido acético glacial, moderadamente solúvel em etanol e praticamente insolúvel em anidrido acético ou em éter. O pH da solução é 4-5. O ponto de fusão é 193 ° -198 ° C
Cada comprimido de 20 mg contém 22,6 mg de pantoprazol (Tazol-IT) sesqui-hidrato de sódio equivalente a 20 mg de pantoprazol (Tazol-IT).
Pantoprazol (Tazol-IT) também contém os seguintes excipientes: Crospovidona, óxido de ferro amarelo E172, hipromelose 2910, copolímero de ácido metilacrílico-etil acrilato (1: 1) polissorbato 80, carbonato de sódio, dióxido de titânio E171, citrato de trietil; manitol (aproximadamente 0,0036 BU) povidona K90, estearato de cálcio, povidona K25, propileno glicol, lauril sulfato de sódio; tinta de impressão (apenas para comprimidos) celulose microcristalina, povidona, dodecil sulfato de sódio.